» Articles » PMID: 19244046

Renal Cell Carcinoma: Dynamic Contrast-enhanced MR Imaging for Differentiation of Tumor Subtypes--correlation with Pathologic Findings

Overview
Journal Radiology
Specialty Radiology
Date 2009 Feb 27
PMID 19244046
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To retrospectively evaluate whether the enhancement patterns of pathologically proved clear cell, papillary, and chromophobe renal cell carcinomas (RCCs) measured on clinical dynamic contrast agent-enhanced magnetic resonance (MR) images permit accurate diagnosis of RCC subtype.

Materials And Methods: This study was Institutional Review Board approved and HIPAA compliant; informed consent was waived. One hundred twelve patients (76 men, 36 women; age range, 25-88 years; mean age, 58.1 years) underwent MR imaging of 113 renal masses (mean diameter, 5.4 cm) with pathologic diagnoses of clear cell (n = 75), papillary (n = 28), or chromophobe (n = 10) RCC. A 1.5-T clinical MR protocol was used before and after (corticomedullary and nephrographic phases) intravenous administration of contrast agent. Region-of-interest measurements within tumor and uninvolved renal cortex were used to calculate percentage signal intensity change and tumor-to-cortex enhancement index. Subtype groups were compared by using linear mixed-effects models. Receiver operating characteristic (ROC) curve analysis was performed for the comparison of clear cell and papillary RCCs.

Results: On both the corticomedullary and nephrographic phase images, clear cell RCCs showed greater signal intensity change (205.6% and 247.1%, respectively) than did papillary RCCs (32.1% and 96.6%, respectively) (P < .001). Chromophobe RCCs showed intermediate change (109.9% and 192.5%, respectively). The tumor-to-cortex enhancement indexes at corticomedullary and nephrographic phases were largest for clear cell RCCs (1.4 and 1.2, respectively), smallest for papillary RCCs (0.2 and 0.4, respectively), and intermediate for chromophobe RCCs (0.6 and 0.8, respectively). Signal intensity changes on corticomedullary phase images were the most effective parameter for distinguishing clear cell and papillary RCC (area under ROC curve, 0.99); a threshold value of 84% permitted distinction with 93% sensitivity and 96% specificity.

Conclusion: Clear cell, papillary, and chromophobe RCCs demonstrate different patterns of enhancement on two-time point clinical dynamic contrast-enhanced MR images, allowing their differentiation with high sensitivity and specificity.

Citing Articles

Computed tomography and magnetic resonance imaging characteristics of renal cell carcinoma: Differences between subtypes and clinical evaluation.

Baytok A, Ecer G, Balasar M, Koplay M J Clin Imaging Sci. 2025; 15:10.

PMID: 40041438 PMC: 11878704. DOI: 10.25259/JCIS_160_2024.


Exploring the value of arterial spin labeling and six diffusion MRI models in differentiating solid benign and malignant renal tumors.

Gao M, Li S, Yuan G, Qu W, He K, Liao Z Eur Radiol Exp. 2024; 8(1):135.

PMID: 39636532 PMC: 11621297. DOI: 10.1186/s41747-024-00537-y.


Diagnostic accuracy of the Clear Cell Likelihood Score and selected MRI parameters in the characterization of indeterminate renal masses - a single-institution study.

Blachura T, Matusik P, Kowal A, Radzikowska J, Jarczewski J, Skiba L Abdom Radiol (NY). 2024; 49(11):3893-3901.

PMID: 38980404 PMC: 11519214. DOI: 10.1007/s00261-024-04484-5.


Clinical T1/2 renal cell carcinoma: multiparametric dynamic contrast-enhanced MRI features-based model for the prediction of individual adverse pathology.

Wang K, Guo B, Yao Z, Li G World J Surg Oncol. 2024; 22(1):145.

PMID: 38822338 PMC: 11143715. DOI: 10.1186/s12957-024-03431-4.


Characterization of renal masses with MRI-based radiomics: assessment of inter-package and inter-observer reproducibility in a prospective pilot study.

Al-Mubarak H, Bane O, Gillingham N, Kyriakakos C, Abboud G, Cuevas J Abdom Radiol (NY). 2024; 49(10):3464-3475.

PMID: 38467854 DOI: 10.1007/s00261-024-04212-z.